Glenview Trust co boosted its position in shares of Aflac Incorporated (NYSE:AFL – Free Report) by 1.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,643 shares of the financial services provider’s stock after buying an additional 186 shares during the quarter. Glenview Trust co’s holdings in Aflac were worth $1,928,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of AFL. Patten & Patten Inc. TN boosted its holdings in Aflac by 4.2% in the fourth quarter. Patten & Patten Inc. TN now owns 4,541 shares of the financial services provider’s stock valued at $470,000 after acquiring an additional 183 shares during the last quarter. Harbour Investments Inc. lifted its position in Aflac by 3.8% during the 4th quarter. Harbour Investments Inc. now owns 5,629 shares of the financial services provider’s stock valued at $582,000 after purchasing an additional 204 shares during the period. Envestnet Portfolio Solutions Inc. boosted its stake in shares of Aflac by 3.3% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 27,717 shares of the financial services provider’s stock valued at $2,867,000 after purchasing an additional 876 shares during the last quarter. one8zero8 LLC acquired a new stake in shares of Aflac during the 4th quarter worth approximately $679,000. Finally, Choate Investment Advisors raised its stake in shares of Aflac by 1.3% during the fourth quarter. Choate Investment Advisors now owns 36,474 shares of the financial services provider’s stock worth $3,773,000 after buying an additional 454 shares during the last quarter. 67.44% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of analysts have commented on AFL shares. Morgan Stanley lifted their target price on shares of Aflac from $98.00 to $105.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. Wells Fargo & Company dropped their price objective on Aflac from $104.00 to $102.00 and set an “equal weight” rating for the company in a report on Wednesday, February 19th. Piper Sandler reduced their target price on Aflac from $122.00 to $118.00 and set an “overweight” rating on the stock in a report on Friday, February 7th. BMO Capital Markets started coverage on Aflac in a research note on Thursday, January 23rd. They issued a “market perform” rating and a $111.00 price target for the company. Finally, Evercore ISI cut their price target on shares of Aflac from $104.00 to $102.00 and set an “underperform” rating on the stock in a research report on Wednesday, December 4th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $103.36.
Insider Buying and Selling
In related news, EVP Audrey B. Tillman sold 24,744 shares of Aflac stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $103.40, for a total transaction of $2,558,529.60. Following the completion of the transaction, the executive vice president now owns 222,618 shares in the company, valued at approximately $23,018,701.20. This trade represents a 10.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Charles D. Lake II sold 29,802 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $107.29, for a total value of $3,197,456.58. Following the completion of the sale, the director now owns 49,962 shares in the company, valued at $5,360,422.98. This represents a 37.36 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 55,546 shares of company stock worth $5,863,616. Insiders own 0.90% of the company’s stock.
Aflac Price Performance
NYSE AFL opened at $107.44 on Monday. The firm’s 50 day moving average is $105.37 and its 200-day moving average is $107.68. The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $58.72 billion, a PE ratio of 11.19, a price-to-earnings-growth ratio of 3.24 and a beta of 0.93. Aflac Incorporated has a 12-month low of $79.31 and a 12-month high of $115.50.
Aflac (NYSE:AFL – Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The financial services provider reported $1.56 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.07). Aflac had a net margin of 28.76% and a return on equity of 16.20%. Equities research analysts anticipate that Aflac Incorporated will post 6.88 earnings per share for the current fiscal year.
Aflac Company Profile
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.
Featured Articles
- Five stocks we like better than Aflac
- How to Buy Cheap Stocks Step by Step
- How to Build the Ultimate Everything ETF Portfolio
- What to Know About Investing in Penny Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- 3 Dividend Kings To Consider
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding AFL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aflac Incorporated (NYSE:AFL – Free Report).
Receive News & Ratings for Aflac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aflac and related companies with MarketBeat.com's FREE daily email newsletter.